Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.130 +0.550 (+21.32%)
Streaming Delayed Price Updated: 3:39 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science
Via Investor Brand Network
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
Via Investor Brand Network
New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
Via Investor Brand Network
Breaking Down Clene: 4 Analysts Share Their Views
Via Benzinga
Clene: Q4 Earnings Insights
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
Via Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
--News Direct-- 
Via News Direct
A Comparison Between ALS, Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
Via Investor Brand Network
7 Underappreciated Penny Stocks That Pack a Wallop
Although extreme speculation inherently attracts astounding risks, these underappreciated penny stocks could beat the odds. 
Via InvestorPlace
New MRI Procedure Eases Multiple Sclerosis Diagnosis
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Via Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. 
Via TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
Via Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
Via Investor Brand Network
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
Via Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
Via Investor Brand Network
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.